Elan Developing Antegren For Chronic MS; Quarterly Sales Up 50%
Elan will pursue development of Antegren (natalizumab) humanized monoclonal antibody for chronic treatment of multiple sclerosis, the company announced July 26.
Elan will pursue development of Antegren (natalizumab) humanized monoclonal antibody for chronic treatment of multiple sclerosis, the company announced July 26.